Who are Visipaque - Hydrocortancyl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VISIPAQUE 270, contrast agent (iodixanol), Iodixanol (Visipaque).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/visipaque-hydrocortancyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Visipaque - Hydrocortancyl — Competitive Intelligence Brief

Visipaque - Hydrocortancyl (Visipaque - Hydrocortancyl) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-ionic iso-osmolar contrast medium. Area: Diagnostic Imaging.

marketed Non-ionic iso-osmolar contrast medium Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Visipaque - Hydrocortancyl (Visipaque - Hydrocortancyl) — Assistance Publique - Hôpitaux de Paris. Visipaque is a non-ionic, iso-osmolar contrast medium that enhances radiographic visualization of blood vessels and organs during diagnostic imaging procedures.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Visipaque - Hydrocortancyl TARGET	Visipaque - Hydrocortancyl	Assistance Publique - Hôpitaux de Paris	marketed	Non-ionic iso-osmolar contrast medium
VISIPAQUE 270	VISIPAQUE 270	Bracco Diagnostics, Inc	marketed	Non-ionic iso-osmolar contrast medium
contrast agent (iodixanol)	contrast agent (iodixanol)	Seoul National University Bundang Hospital	marketed	Non-ionic iso-osmolar contrast medium
Iodixanol (Visipaque)	Iodixanol (Visipaque)	Chinese PLA General Hospital	marketed	Non-ionic iso-osmolar contrast medium

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-ionic iso-osmolar contrast medium class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Bracco Diagnostics, Inc · 1 drug in this class
Chinese PLA General Hospital · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Visipaque - Hydrocortancyl — Competitive Intelligence Brief. https://druglandscape.com/ci/visipaque-hydrocortancyl. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab